Literature DB >> 33594311

SNHG3 promotes migration, invasion, and epithelial-mesenchymal transition of breast cancer cells through the miR-186-5p/ZEB1 axis.

Qun Wan1, Min Tang1, Shi-Lei Sun1, Jing Hu1, Zi-Jiu Sun1, Yu-Ting Fang1, Tong-Chuan He2, Yan Zhang1.   

Abstract

Increasing evidence suggests that the long non-coding RNAs (lncRNAs) participate in the development and progression of breast cancer. The lncRNA small nucleolar RNA host gene 3 (SNHG3) reportedly acts as an oncogene in hepatocellular carcinoma and colorectal cancer; however, little is known about the biological function and oncogenic mechanisms of SNHG3 in breast cancer. We demonstrated that the expression of SNHG3 was abnormally high in breast cancer tissues and cells, and transgenic expression of SNHG3 promoted the proliferation, migration, and invasion of breast cancer cell lines (MCF-7 and MDA-MB-231). The mean volume of the xenografts from the SNHG3-knockdown MCF-7 cells was lower than that of the control tumor cells. Moreover, the expression of zinc finger E-box binding homeobox 1 (ZEB1) increased after SNHG3 overexpression and vice versa. Overexpression of ZEB1 triggered cellular migration and invasion behaviors. Analysis of the mechanism underlying these effects suggested that SNHG3 is an effective sink for miR-186-5p and modulates ZEB1 repression, conferring an additional level to its post-transcriptional regulation. In conclusion, SNHG3 promotes the migration and invasion of breast cancer cells through miR-186-5p/ZEB1 regulation and the induction of the epithelial to mesenchymal transition, indicating that SNHG3 is a potential treatment target for breast cancer. AJTR
Copyright © 2021.

Entities:  

Keywords:  Long non-coding RNA; SNHG3; ZEB1; breast cancer; epithelial to mesenchymal transition

Year:  2021        PMID: 33594311      PMCID: PMC7868844     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  8 in total

1.  Long noncoding RNA SNHG3 promotes malignant phenotypes in cervical cancer cells via association with YAP1.

Authors:  Hongyu Zhu; Chenyu Zhu; Xiang Feng; Youzhen Luo
Journal:  Hum Cell       Date:  2021-11-24       Impact factor: 4.174

2.  Long noncoding RNA SNHG6 promotes papillary thyroid cancer cells proliferation via regulating miR-186/CDK6 axis.

Authors:  Jian Xu; Miaomiao Liao
Journal:  Gland Surg       Date:  2021-10

Review 3.  Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and other tumour progression.

Authors:  Dan-Dan Shan; Qiu-Xian Zheng; Jing Wang; Zhi Chen
Journal:  World J Gastroenterol       Date:  2022-04-28       Impact factor: 5.374

4.  SNHG3 could promote prostate cancer progression through reducing methionine dependence of PCa cells.

Authors:  Xiaotian Wang; Yongsheng Song; Yaxing Shi; Da Yang; Jiaxing Li; Bo Yin
Journal:  Cell Mol Biol Lett       Date:  2022-02-05       Impact factor: 5.787

5.  Prognostic Role and Potential Mechanisms of N6-methyladenosine-related Long Noncoding RNAs in Hepatocellular Carcinoma.

Authors:  Tianxing Dai; Jing Li; Linsen Ye; Haoyuan Yu; Mingbin Deng; Wei Liu; Hua Li; Yang Yang; Guoying Wang
Journal:  J Clin Transl Hepatol       Date:  2021-07-13

6.  Systematic pan-cancer analysis on the expression and role of regulator of chromatin condensation 1/small nucleolar RNA host gene 3/small nucleolar RNA host gene 12.

Authors:  Kai Hu; Huomei Yu; Shiyan Liu; Deyu Liao; Yan Zhang
Journal:  Front Mol Biosci       Date:  2022-09-06

7.  LncRNA KRT19P3 Is Involved in Breast Cancer Cell Proliferation, Migration and Invasion.

Authors:  Yanping Fan; Xiaotong Dong; Meizeng Li; Pengju Liu; Jie Zheng; Hongli Li; Yunxiang Zhang
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

8.  Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.

Authors:  Pengcheng Zhou; Yuhua Lu; Yewei Zhang; Lei Wang
Journal:  Front Oncol       Date:  2021-07-02       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.